Chromosome 5q deletion is extremely rare in patients with myelofibrosis

Koichi Takahashi; Jorge Cortes; Sherry Pierce; Lynne Abruzzo; Hagop Kantarjian; Srdan Verstovsek

doi:10.1016/j.leukres.2013.01.003

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

Koichi Takahashi, Jorge Cortes, Sherry Pierce, Lynne Abruzzo, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.

Original language	English (US)
Pages (from-to)	552-555
Number of pages	4
Journal	Leukemia Research
Volume	37
Issue number	5
DOIs	https://doi.org/10.1016/j.leukres.2013.01.003
State	Published - May 2013
Externally published	Yes

Keywords

5q deletion
Lenalidomide
Myelofibrosis

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2013.01.003

Cite this

@article{57acc24e5b424da09aba038cddeda7d6,

title = "Chromosome 5q deletion is extremely rare in patients with myelofibrosis",

abstract = "Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.",

keywords = "5q deletion, Lenalidomide, Myelofibrosis",

author = "Koichi Takahashi and Jorge Cortes and Sherry Pierce and Lynne Abruzzo and Hagop Kantarjian and Srdan Verstovsek",

year = "2013",

month = may,

doi = "10.1016/j.leukres.2013.01.003",

language = "English (US)",

volume = "37",

pages = "552--555",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Chromosome 5q deletion is extremely rare in patients with myelofibrosis

AU - Takahashi, Koichi

AU - Cortes, Jorge

AU - Pierce, Sherry

AU - Abruzzo, Lynne

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2013/5

Y1 - 2013/5

N2 - Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.

AB - Chromosome 5q deletion can be found in rare cases of myelofibrosis (MF) but the incidence, clinical significance and response to therapies are not well studied. We retrospectively reviewed charts of 939 patients with MF and identified 8 patients [0.8%] who carried 5q deletion. Of the 8, seven had complex cytogenetic abnormalities and one had additional clone with different cytogenetic abnormality. All 8 had significant three-lineage pancytopenia. Three patients took lenalidomide and one (patient with 5q-clone) achieved long-lasting hematologic response. Two patients responded to JAK2 inhibitor therapy. MF patients with 5q deletion often have complex karyotype and poor outcome.

KW - 5q deletion

KW - Lenalidomide

KW - Myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84875875412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875875412&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.01.003

DO - 10.1016/j.leukres.2013.01.003

M3 - Article

C2 - 23391517

AN - SCOPUS:84875875412

SN - 0145-2126

VL - 37

SP - 552

EP - 555

JO - Leukemia Research

JF - Leukemia Research

IS - 5

ER -

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this